Anbio Biotechnology (NNNN) Fair Value 2026

NNNN · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (80/100)

Quick Summary — As of 2026-08-28, Anbio Biotechnology (NNNN) trades at $7.67. QOC: 2.4/10. Value Trap Risk: 80/100 (DANGER). 1/13 models active.

Key Facts

Ticker
NNNN
Price
$7.67
Quality Score
2.4/10
Value Trap Risk
80/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 80 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give NNNN?

1 Intrinsic Value Models vs. Current Price ($7.67)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $0.47 -93.9%

All Models Active

All 1 models are displayed above.

What Is Anbio Biotechnology (NNNN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Anbio Biotechnology's intrinsic value is estimated at $0.47. Trading at its current price of $7.67, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -93.9%.

What Do the Models Say About NNNN?

1 of 13 models are currently active for NNNN. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does NNNN Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, NNNN ranks #56 by Quality of Company score. CirclFi's QOC score of 2.4/10 evaluates 32 fundamental signals. A score of 2.4 signals below-average fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Anbio Biotechnology operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is NNNN a Value Trap?

CirclFi's Value Trap algorithm assigns NNNN a score of 80/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Anbio Biotechnology. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Anbio Biotechnology earns a quality score of 2.4/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NNNN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NNNN's 1 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Anbio Biotechnology Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

9 related Medical Instruments & Supplies stocks with 13-model coverage

ALCAlcon Inc.QOC 2.7ISRGIntuitive Surgical, Inc.QOC 9.4ZJYLJin Medical International Ltd.QOC 2.9RMDResMed Inc.QOC 9.4TUTHStandard Dental Labs Inc.QOC 3.2LMATLeMaitre Vascular, Inc.QOC 9.3EMBCEmbecta Corp.QOC 7.8ANGOAngioDynamics, Inc.QOC 6.7HBIOHarvard Bioscience, Inc.QOC 5.8

Read investment analysis: ALC · ISRG · ZJYL · RMD · TUTH · LMAT · EMBC · ANGO · HBIO

Which Other Stocks Have a Similar Quality Score to NNNN?

7 companies across all industries closest to NNNN’s Quality of Company score of 2.4/10.

TNMGTNL MediageneQOC 2.4WCTWellchange Holdings Company LimitedQOC 2.4DSYBig Tree Cloud Holdings LimitedQOC 2.4AXGSolowin HoldingsQOC 2.4ASAmer Sports, Inc.QOC 2.4MATHMetalpha Technology Holding LimitedQOC 2.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TNMG · WCT · DSY · AXG · AS · MATH · NVDA

Where Does NNNN Sit in CirclFi's Medical Instruments & Supplies Rankings?

NNNN is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Anbio Biotechnology’s Valuation?

What is Anbio Biotechnology's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Anbio Biotechnology (NNNN). The Quality of Company score is 2.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NNNN overvalued or undervalued right now?

At $7.67, 0 of 1 active models suggest NNNN may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Anbio Biotechnology's business model in Medical Instruments & Supplies.

What does a Quality of Company score of 2.4 mean for NNNN?

Anbio Biotechnology's QOC of 2.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NNNN?

CirclFi analyzes NNNN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is NNNN a value trap in 2026?

Anbio Biotechnology's Value Trap score is 80/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Anbio Biotechnology (NNNN) a Quality of Company score of 2.4/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/NNNN/ · Methodology
Primary sources for this NNNN valuation
  • Financial statements: Anbio Biotechnology 10-K and 10-Q filings on SEC EDGAR (CIK 0001982708) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NNNN as of ; valuations recomputed .